Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses
- PMID: 26039526
- DOI: 10.1097/HJH.0000000000000614
Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses
Abstract
Background and objectives: We have recently published an overview and meta-analysis of the effects of the five major classes of blood pressure-lowering drugs on cardiovascular outcomes when compared with placebo. However, possible differences in effectiveness of the various classes can correctly be estimated only by head-to-head comparisons of different classes of agents. This has been the objective of a new survey and meta-analysis.
Methods: A database search between 1966 and August 2014 ide ntified 50 eligible randomized controlled trials for 58 two-drug comparisons (247 006 patients for 1 029 768 patient-years). Risk ratios and their 95% confidence intervals of seven outcomes were estimated by a random-effects model.
Results: The effects of all drug classes are not significantly different on most outcomes when their blood pressure effect is equivalent. However, there are also significant differences involving almost all classes of drugs. When compared to all other classes together, diuretics are superior in preventing heart failure; beta-blockers less effective in preventing stroke; calcium antagonists superior in preventing stroke and all-cause death, but inferior in preventing heart failure; angiotensin-converting enzyme inhibitors more effective in preventing coronary heart disease and less in preventing stroke; angiotensin receptor blockers inferior in preventing coronary heart disease; and renin-angiotensin system blockers more effective in preventing heart failure. When stratifying randomized controlled trials according to total cardiovascular risk, no drug class was found to change in effectiveness with the level of risk.
Conclusions: The results of all available evidence from head-to-head drug class comparisons do not allow the formulation of a fixed paradigm of drug choice valuable for all hypertensive patients, but the differences found may suggest specific choices in specific conditions, or preferable combinations of drugs.
Similar articles
-
Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses.J Hypertens. 2015 Feb;33(2):195-211. doi: 10.1097/HJH.0000000000000447. J Hypertens. 2015. PMID: 25485720 Review.
-
Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure--meta-analyses of randomized trials.J Hypertens. 2016 Mar;34(3):373-84; discussion 384. doi: 10.1097/HJH.0000000000000848. J Hypertens. 2016. PMID: 26780184
-
Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis.J Hypertens. 2018 Aug;36(8):1637-1647. doi: 10.1097/HJH.0000000000001777. J Hypertens. 2018. PMID: 29847487 Review.
-
Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials.J Hypertens. 2016 Oct;34(10):1921-32. doi: 10.1097/HJH.0000000000001052. J Hypertens. 2016. PMID: 27454050 Review.
-
Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis.J Hypertens. 2018 Jun;36(6):1256-1265. doi: 10.1097/HJH.0000000000001720. J Hypertens. 2018. PMID: 29543625
Cited by
-
The Increasing Problem of Resistant Hypertension: We'll Manage till Help Comes!Med Sci (Basel). 2024 Oct 4;12(4):53. doi: 10.3390/medsci12040053. Med Sci (Basel). 2024. PMID: 39449409 Free PMC article. Review.
-
Losartan as a Reproposing Therapeutic Agent in Acute Respiratory Distress Syndrome: Modulating Inflammatory Responses and Cytokine Production.Int J Mol Cell Med. 2024;13(2):120-132. doi: 10.22088/IJMCM.BUMS.13.2.120. Int J Mol Cell Med. 2024. PMID: 39184821 Free PMC article.
-
Outpatient management of essential hypertension: a review based on the latest clinical guidelines.Ann Med. 2024 Dec;56(1):2338242. doi: 10.1080/07853890.2024.2338242. Epub 2024 Apr 11. Ann Med. 2024. PMID: 38604225 Free PMC article. Review.
-
Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines.Hypertension. 2024 May;81(5):1021-1030. doi: 10.1161/HYPERTENSIONAHA.124.22821. Epub 2024 Mar 13. Hypertension. 2024. PMID: 38477109 Free PMC article.
-
Comparing Cardiovascular Outcomes and Costs of Perindopril-, Enalapril- or Losartan-Based Antihypertensive Regimens in South Africa: Real-World Medical Claims Database Analysis.Adv Ther. 2023 Nov;40(11):5076-5089. doi: 10.1007/s12325-023-02641-8. Epub 2023 Sep 21. Adv Ther. 2023. PMID: 37730949 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
